EIKCS 2021: Future treatments for metastatic kidney cancer
Despite the advances in first-line treatments for metastatic renal cell [...]
CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival
The US Food and Drug Administration (FDA) has granted the [...]
IKCS 2020: Treatment selection in kidney cancer
During this interview, Dr Rana McKay from the University of [...]
FDA grants Fast Track designation to glutaminase inhibitor combination for metastatic kidney cancer
The glutaminase inhibitor, CB-839 has been granted Fast Track designation [...]
FDA grants fast track designation to glutaminase inhibitor CB-839 in combination with cabozantinib for metastatic kidney cancer
Calithera Biosciences announced earlier this week that the US Food [...]
A new drug to treat solid tumours
The following blog from Mesothelioma.net gives a good summary of [...]
Initiation of phase 2 clinical trial of glutaminase inhibitor plus everolimus for renal cell carcinoma
Calithera Biosciences, an American pharmaceutical company focused on developing drugs [...]
